Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 06:30:00 16/01/2026 GMT			5-day change	1st Jan Change
3,309.00 ^JPY	-2.71%		-6.58%	-1.16%

01-13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
01-12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM

Transcript : Daiichi Sankyo Company, Limited - Special Call

Published on 10/21/2025 at 03:20 pm BST - Modified on 10/27/2025 at 12:25 pm GMT

S&P Capital IQ

Presenter Speech
Kentaro Asakura (Executives)

Thank you for waiting, everybody. We'll now start Daiichi Sankyo's ESMO 2025 Highlights. This is Ken Asakura from Corporate Communications, and I will be

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

01-13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
01-12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
01-07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
01-05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
01-02	Daiichi Sankyo to spend roughly 300 billion yen to set up production facilities for targeted cancer medicine, Nikkei reports	RE
12-29	Cardiogeni swings to loss as Daiichi Sankyo deal drops away	AN
12-28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI
12-24	Daiichi Sankyo Announces Approval of ENHERTU® in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies	CI
12-22	AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial	MT
12-22	AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US	MT
12-22	AstraZeneca says lung cancer trial fails to meet survival target	AN
12-22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US	MT
12-22	Harbour Energy makes USD3.2 billion US buy	AN
12-22	Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer	CI
12-21	Daiichi Sankyo Company, Limited Destiny-Endometrial02 Phase 3 Trial of Enhertu Initiated as Adjuvant Therapy in Patients with Her2 Expressing Endometrial Cancer	CI
12-19	Language in health research grants is changing under political pressure	RE
12-18	Daiichi Sankyo, AstraZeneca apply for second EU approval for Datroway	AN
12-18	Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy	CI
12-16	AstraZeneca and Daiichi Sankyo's Enhertu approved as first-line therapy for HER2+ breast cancer
12-16	AstraZeneca, Daiichi Sankyo Drug Gets U.S. Nod for Breast-Cancer Label Expansion	DJ
12-16	AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US	MT
12-16	UK Stocks-Factors to watch on December 16	RE
12-16	AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment	MT
12-16	Daiichi Sankyo Company, Limited - Special Call
12-16	U.S. FDA Clears AstraZeneca, Daiichi Sankyo Breast Cancer Drug	MT